Related Experiment Video
Updated: Sep 29, 2025
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
15.0K
[Tumor markers in urological cancers: an update.]
José Rubio-Briones1, Ángel Borque-Fernando2
1Director Clínica de Urología. Hospital VITHAS 9 de Octubre. Valencia. España.
Archivos Espanoles De Urologia
|March 25, 2022
Summary
Commercial pressures can lead to the misuse of tumor biomarker tests, extending their application beyond validated purposes. This highlights the need for strict adherence to regulatory standards in biomarker research and clinical use.
Area of Science:
- Oncology
- Biomarker Research
- Regulatory Science
Background:
- Tumor biomarker research is critical for cancer diagnosis and treatment.
- Commercialization of biomarkers faces stringent regulatory oversight.
- Widespread use across diverse populations can introduce unintended applications.
Purpose of the Study:
- To examine the impact of commercial pressures on the application of tumor biomarkers.
- To assess the potential for off-label use of biomarkers due to market demands.
- To underscore the importance of adhering to validated indications for biomarker tests.
Main Methods:
- Review of regulatory guidelines for biomarker commercialization.
- Analysis of market trends and pressures in oncology diagnostics.
- Case study examination of biomarker application scope.
Main Results:
- Commercialization of tumor biomarkers is governed by strict regulations.
- Market pressures can inadvertently lead to the expansion of biomarker use beyond tested applications.
- Unconscious extension of use to untested objectives is a recognized risk.
Conclusions:
- Strict adherence to regulatory standards is essential for safe and effective biomarker use.
- The potential for off-label use necessitates ongoing vigilance and clear communication.
- Balancing commercial interests with patient safety is paramount in biomarker development and deployment.
